November 2012: Regenera Pharma Ltd. Successfully completed Phase 1 study in Healthy volunteers


Phase 1 took place at INC Research’s Early Phase unit in Toronto and assessed the safety and tolerability of subcutaneous RPh201 administration in healthy volunteers following single and multiple ascending doses.

RPh201 was found safe and well tolerable at all tested doses. Health Canada approved to use highest tested dose in patients with moderate-to-severe Alzheimer’s disease.